# Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

> **NCT01872182** · PHASE3 · TERMINATED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 200 (actual)

## Conditions studied

- Abdominal Obesity Metabolic Syndrome

## Interventions

- **DRUG:** ALS-L1023
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01872182
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01872182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01872182, "Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01872182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*